{Reference Type}: Case Reports
{Title}: Nirmatrelvir Resistance-de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure-a Case Report.
{Author}: Zuckerman NS;Bucris E;Keidar-Friedman D;Amsalem M;Brosh-Nissimov T;
{Journal}: Clin Infect Dis
{Volume}: 78
{Issue}: 2
{Year}: 2024 02 17
{Factor}: 20.999
{DOI}: 10.1093/cid/ciad494
{Abstract}: Resistance of SARS-CoV-2 to antivirals was shown to develop in immunocompromised individuals receiving remdesivir. We describe an immunocompromised patient who was treated with repeated and prolonged courses of nirmatrelvir and developed de-novo E166V/L50F mutations in the Mpro region. These mutations were associated with clinical and virological treatment failure.